Rajesh Kumar’s Post

We are pleased to announce that US FDA has approved IND for our asset AUR-112, a potent and selective inhibitor of MALT1, being developed for the treatment of lymphoid malignancies. With desirable free fraction and potency in human whole blood assay, AUR-112 may add clinical value to patients. This milestone is a testament to the team's hard work and dedication, reaffirming our commitment to developing innovative therapeutics for cancer patients worldwide. #MALT1 #Oncology #Cancer #DrugDiscovery #INDapprovals #CancerTherapies #CancerDrugs #FDAapprovals #Lymphoma #CancerTreatment #IndiaDrugDiscovery #OncologyPipeline #CancerDrugPipeline #NovelTherapeutics #OncologyTargets

Highly recommended this webinar relevant for any one involved in the treatment of patients with lung cancer. Learn everything about drug-drug interactions, the pros and cons of TDM, and management of toxicity, including discussion of ESMO - European Society for Medical Oncology guidelines. You are all welcome!!

For National Cancer Research Month, we want to say thank you to our team and the researchers, clinicians, and patients who are taking part in clinical trials to advance new therapeutics. We've made important progress, but there is still much to be done. Together, we can push forward and make a difference in the lives of those affected by #cancer. Learn more about our #clinicaltrials and the contributions Janux is making to #cancerresearch: https://lnkd.in/ggvVSxn3 #NCRM24 #CancerResearchSavesLives #TCellEngagers #cancer #oncology #immunotherapy #immunomodulators

The year 2018 marked 40 years since the U.S. FDA approved the first platinum-based cancer drug, cisplatin. Here is a look at how these drugs work and their versions across the globe. #Cancer #Oncology #PlatinumCancerDrugs #Cisplatin #Carboplatin #Oxaliplatin

After decades of fitful progress, therapeutic cancer vaccines are moving forward. Manufacturers face key development decisions that will affect perceptions of these innovative therapies in the future. Learn more: https://bit.ly/3VCxPdq #cancervaccines #oncology

Precision Over Power: Treatments in Lung Cancer Lung cancer is not just a diagnosis; it's a profound battle that affects patients and their loved ones in unimaginable ways. Chemotherapy-free, targeted therapies offering hope for better outcomes and quality of life. In my latest article in The Times Of India, I explore these groundbreaking advancements, particularly in treating EGFR-mutated NSCLC, and how new combinations like RYBREVANT® plus LAZCLUZE™ are redefining the fight against lung cancer. #LungCancer #Oncology #PrecisionMedicine #TargetedTherapies #HealthcareInnovation #EGFR #CancerTreatment #Pharma #MedicalResearch

Precision Over Power: The Rise of Chemotherapy-Free Treatments in Lung Cancer 🌟 Lung cancer is not just a diagnosis; it's a profound battle that affects patients and their loved ones in unimaginable ways. As traditional chemotherapy often brings harsh side effects, a new era is emerging with chemotherapy-free, targeted therapies offering hope for better outcomes and quality of life. In my latest article, I explore these groundbreaking advancements, particularly in treating EGFR-mutated NSCLC, and how new combinations like RYBREVANT® plus LAZCLUZE™ are redefining the fight against lung cancer. Read on to discover how these innovative treatments are paving the way for a future where precision triumphs over power. 💊🔬 #LungCancer #Oncology #PrecisionMedicine #TargetedTherapies #HealthcareInnovation #EGFR #CancerTreatment #Pharma #MedicalResearch

Congratulations to everyone at Iovance Biotherapeutics, Inc., for achieving the first-ever FDA approval of a TIL (tumor-infiltrating lymphocyte) therapy. It represents many years of immense contributions from so many dedicated individuals and provides an important new treatment option and hope for people with advanced melanoma. This historic milestone further validates the clinical efficacy of TILs, and importantly, paves the way for the advancement of the next-generation of TIL therapies, including Turnstone’s "Selected TILs", which we are developing to drive efficacy across a greater breadth of solid tumors. To learn more about Selected TILs and our differentiated approach to TIL therapy, please visit => https://lnkd.in/gkSz9xVj. #TSBX #SelectedTIL #tumorinfiltratinglymphocytes #TILtherapy #celltherapy #immunotherapy #oncology #immunooncology #cancertreatment #oncologyresearch #cancer #lifesciences #cancerresearch #clinicaltrials #researchanddevelopment #clinicalresearch #biopharma #team #opportunities #people #leadership #biotechnology #cellandgenetherapy

After decades of fitful progress, therapeutic cancer vaccines are moving forward. Manufacturers face key development decisions that will affect perceptions of these innovative therapies in the future. Learn more: #cancervaccines #oncology

As CG Oncology's $380M IPO earlier this year or the continuing buzz around mRNA-4517/V940 indicate, cancer vaccines and oncolytic viruses are poised to help more patients and potentially realize commercial success. In addition to demonstrating success in the clinic, these therapies (mRNA-based therapies in particular) must navigate unique barriers to successful commercialization. My colleagues describe these barriers and how to mitigate them in this article.